Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.
Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflammatory drugs, colchicine, steroids, statins and thalidomide have all been tried. Recently, some patients have demonstrated a good clinical response to either etanercept or anakinra. We report a case of a 10-year-old girl who experienced prolonged and severe inflammatory attacks, when she was treated with etanercept, and later with anakinra.
Shendi
Hiba M
HM
Royal Victoria Hospital, Belfast, Northern Ireland, UK. hiba.shendi@belfasttrust.hscni.net
Walsh
Deirdre
D
Edgar
J David M
JD
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D000068800:Etanercept; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000009:adverse effects* / Q000627:therapeutic use*; D054078:Mevalonate Kinase Deficiency / Q000188:drug therapy* / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept